References
- MinardiDd’AnzeoGCantoroDContiIAMuzzonigroGUrinary tract infections in women: etiology and treatment optionsInt J Gen Med2011433334321674026
- GrabeMBjeklund-JohansenTEBottoHGuidelines on Urological InfectionsArnheimEuropean Association of Urology2010 Available from: www.uroweb.org/gls/pdf/Urological%20Infections%202010.pdfAccessed June 15, 2011
- BauerHWRahlfsVWLauenerPABlessmannGSPrevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studiesInt J Antimicrob Agents200219645145612135831
- NaberKGChoYHMatsumotoTSchaefferAImmunoactive prophylaxis of recurrent urinary tract infections: a meta-analysisInt J Antimicrob Agents200933211111918963856
- PisaniEPallaRBonoAVDouble-Blind Randomized Clinical Study of OM-89 vs Placebo in Patients Suffering from Recurrent Urinary Tract InfectionsGenevaOM Pharma (on file)1992
- BauerHWAlloussiSEggerGBlumleinHMCozmaGSchulmanCCMulticenter UTI Study GroupA long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infectionsEur Urol200547454254815774256
- MagasiPPánovicsJIllésANagyMUro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trialEur Urol19942621371407957468
- SchulmanCCCorbusierAMichielsHTaenzerHJOral immunotherapy of recurrent urinary tract infections: a double-blind placebocontrolled multicenter studyJ Urol199315039179218345609
- TammenHImmunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study GroupBr J Urol1990651692178724
- OM PharmaUro-Vaxom®: summary of product characteristicsSwissmedicOM Pharma (on file)2006
Reference
- GrabeMBergland-JohansenTEBottoHGuidelines on urological infectionsPresented at the 25th European Association of Urology Annual CongressBarcelona, SpainApril 16–20, 2010